J-TEC has commissioned Maruho to provide information in Japan on the autologous cultured epidermal sheet Jasmine, with information activities scheduled to begin in April 2027. The two companies entered into an exclusive partnership agreement on 28 October 2026.
Japan Tissue Engineering Co., Ltd. (J-TEC) has commissioned Maruho to provide information on the autologous cultured epidermal sheet Jasmine for vitiligo treatment to medical institutions in Japan that purchase the product. Activities are scheduled to begin in April 2027, and the agreement was signed on 28 October 2026.
Maruho aims to achieve market penetration for Jasmine by leveraging its experience selling pharmaceuticals in dermatology and its medical information network. Under the exclusive partnership agreement, it is expected to conduct information activities through its existing distribution network.
Jasmine is a cell sheet derived from autologous epidermal cells, including melanocytes, and is marketed for the treatment of vitiligo.